Organon & Co.
OGNDividend PayerAutomated dividend-safety read-out from payout, leverage, yield, profitability and track record. See the Financials tab for the full per-statement Financial Investigation. Educational only — not investment advice.
At a glance
Organon & Co. (OGN) operates in the Drug Manufacturers - General industry and is based in the United States. It pays a quarterly dividend of $0.08 a year, a yield of 0.58% at the current price of $13.75. It paid out 10% of its earnings as dividends, leaving most of its profit in the business. 5 analysts cover it; their average 12-month price target of $11.25 is 18.2% below the current price.
Written automatically from the figures on this page, as of Oct 24, 2026. Facts only, not a recommendation.
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis.
Business description sourced from Yahoo Finance / company filings. Not affiliated with SimplyWallStreet.
Key Metrics
Valuation
Profitability
Financial Health
Data provided by Yahoo Finance via yfinance. Updated daily. Not investment advice.